398 related articles for article (PubMed ID: 10663572)
1. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Oka Y; Udaka K; Tsuboi A; Elisseeva OA; Ogawa H; Aozasa K; Kishimoto T; Sugiyama H
J Immunol; 2000 Feb; 164(4):1873-80. PubMed ID: 10657636
[TBL] [Abstract][Full Text] [Related]
3. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.
Ohminami H; Yasukawa M; Fujita S
Blood; 2000 Jan; 95(1):286-93. PubMed ID: 10607714
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
5. WT1 as a novel target antigen for cancer immunotherapy.
Oka Y; Tsuboi A; Elisseeva OA; Udaka K; Sugiyama H
Curr Cancer Drug Targets; 2002 Mar; 2(1):45-54. PubMed ID: 12188920
[TBL] [Abstract][Full Text] [Related]
6. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
7. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
[TBL] [Abstract][Full Text] [Related]
8. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
[TBL] [Abstract][Full Text] [Related]
9. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; Stauss HJ
Blood; 2003 Feb; 101(3):1007-14. PubMed ID: 12393606
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for leukemia targeting the Wilms' tumor gene.
Yasukawa M
Leuk Lymphoma; 2001 Jul; 42(3):267-73. PubMed ID: 11699391
[TBL] [Abstract][Full Text] [Related]
11. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen.
Savage P; Gao L; Vento K; Cowburn P; Man S; Steven N; Ogg G; McMichael A; Epenetos A; Goulmy E; Stauss HJ
Blood; 2004 Jun; 103(12):4613-5. PubMed ID: 14988155
[TBL] [Abstract][Full Text] [Related]
12. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue.
Al Qudaihi G; Lehe C; Negash M; Al-Alwan M; Ghebeh H; Mohamed SY; Saleh AJ; Al-Humaidan H; Tbakhi A; Dickinson A; Aljurf M; Dermime S
Leuk Lymphoma; 2009 Feb; 50(2):260-9. PubMed ID: 19197722
[TBL] [Abstract][Full Text] [Related]
14. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18.
Castellanos MR; Hayes RL; Maiman MA
Gynecol Oncol; 2001 Jul; 82(1):77-83. PubMed ID: 11426965
[TBL] [Abstract][Full Text] [Related]
15. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
Pinilla-Ibarz J; May RJ; Korontsvit T; Gomez M; Kappel B; Zakhaleva V; Zhang RH; Scheinberg DA
Leukemia; 2006 Nov; 20(11):2025-33. PubMed ID: 16990779
[TBL] [Abstract][Full Text] [Related]
16. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in hepatitis B virus X antigen.
Chung MK; Yoon H; Min SS; Lee HG; Kim YJ; Lee TG; Lim JS; Kim CM; Park SN
J Immunother; 1999 Jul; 22(4):279-87. PubMed ID: 10404429
[TBL] [Abstract][Full Text] [Related]
17. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
18. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
[TBL] [Abstract][Full Text] [Related]
19. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Tsuboi A; Oka Y; Udaka K; Murakami M; Masuda T; Nakano A; Nakajima H; Yasukawa M; Hiraki A; Oji Y; Kawakami M; Hosen N; Fujioka T; Wu F; Taniguchi Y; Nishida S; Asada M; Ogawa H; Kawase I; Sugiyama H
Cancer Immunol Immunother; 2002 Dec; 51(11-12):614-20. PubMed ID: 12439606
[TBL] [Abstract][Full Text] [Related]
20. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.
Xiaobing J; Xiaoling L; Ruen L; Fangcheng Z; Hongyang Z
Cancer Biother Radiopharm; 2007 Dec; 22(6):826-35. PubMed ID: 18158774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]